Business Wire

CA-CEPTON-TECHNOLOGIES

Share
Smart Lidar Network Set to Unlock Missing Layer in Surveillance Technology, Live at GSX 2019

A network of laser powered smart sensors that can automatically link with other types of sensors and activate CCTV cameras to provide multi-dimensional surveillance will be launched at Global Security Exchange (GSX) in Chicago next week.

Cepton Technologies’ Helius™ system utilizes the power and accuracy of laser combined with smart AI driven detection and tracking technologies to build a detailed image of activity in a given area, regardless of lighting conditions.

Aimed at seamless integration into existing security systems, Helius is a smart lidar network utilizing edge computing to offer real-time detection, tracking and classification. The Helius system combines full 3D data, dimension, location and velocity, from multiple smart sensors in different locations to allow for comprehensive coverage and real-time monitoring. Users can create and manage event zones and triggers to activate alarms or other types of sensors for further verification, when potential threats are detected.

Ahead of appearing at the GSX between September 8-12, Cepton’s head of product Jerone Floor said: “Being able to link our smart sensors together in a Helius network provides an unprecedented level of coverage to critical areas.

“Helius adds an additional layer to an existing security system, filling the medium-range gap and augmenting it with the capability to classify objects including human, small animals and vehicles, as well as behaviours such as crawling, crouching and running.”

When operating in tandem, the sensors can be used to analyse the same area from multiple different perspectives, eliminating blind spots and ensuring maximum coverage.

“With our low power requirements and high resolution 3D imaging regardless of lighting conditions, the Helius system creates a new era of multi-dimensional security fit for use in almost any environment,” Jerone introduced.

The Helius system consists of a network of smart lidar units called Vista-Edge™, which combines a lidar sensor with a powerful micro-computer in a single package. Powered by Cepton’s patented Micro-Motion Technology (MMT™) system, the Vista-Edge is rotation free and already front facing, so it can fit into a standard security camera housing.

The micro-computer processes the information directly at the ‘edge’* so it highlights only potential threats. Because data processing is done inside the unit, data transmission is kept to a minimum, using only a few kilobytes where video would require several megabytes of storage.

This means each sensor can be deployed using only basic cellular SIM cards – and with minimal power requirements, wireless installation is possible.

And because the Helius perception and networking software is browser-based, you can operate the system on mobiles and tablets to maximize user simplicity.

Neil Huntingdon, Cepton’s VP of Business Development, said: “In the past, the prospect of truly comprehensive surveillance coverage has been limited to deploying multiple cameras across a location, and having someone present to monitor each camera. That’s expensive to deploy and expensive to run, even just in having the data capacity to transmit all that video footage.

“The Helius system delivers absolute coverage with smart monitoring system that gives potential threats no hiding place. This is next-generation security for the connected era.”

Designed with user simplicity in mind, the Helius system can operate over WiFi, cellular networks or Ethernet, and can even be used to monitor traffic – and can identify when packages are left or thrown over fences or walls.

Jerone added: “The unerring accuracy of our system means we zero in on potential threats with, literally, a laser-focus. It can then be used to trigger accompanying security systems, such as cameras, to capture more detailed footage of the perceived threat, or to raise the alarm with security personnel.

“Helius offers a step change in surveillance and security response measures, minimising false positives and false negatives, reducing threat and delivering a drastic improvement in security confidence.”

Formerly the ASIS International Annual Seminar and Exhibits, Global Security Exchange (GSX) is the most relevant and pioneering security event that unites the full spectrum of the industry. Cyber, operational, and physical security professionals from across the private and public sectors, allied organizations and partners, and the industry’s leading solution providers come to GSX for the most comprehensive security education and innovative technology in the world.

Held at McCormack Place, Chicago, Exhibit Hall A, Cepton Technologies will be at stand 1894, next to the bistro. To schedule a meeting onsite, please email: media@cepton.com

*Edge processing

Edge processing refers to the execution of aggregation, data manipulation, bandwidth reduction and other logic directly on an IoT sensor or device. The more work the device can do to prepare the data for the cloud, the less work the cloud needs to do.

About Vista-Edge

Vista-Edge is a smart sensor unit which combines Cepton’s high performance lidar sensor with a powerful edge computing device. Pre-installed with the Helius perception and network software, it is designed to enable Cepton’s eco-system partners to integrate and develop solutions tailored for specific markets. For example, Security, Transport Infrastructure and Retail integrators can now augment traditional solutions with state-of-the-art 3D lidar-based tracking.

Vista-Edge is powered by NVIDIA’s AI computing platform, the Jetson TX2, and functions with Cepton’s portfolio of MMT lidar sensors which provide high resolution and long-range 3D imaging.

Vista-Edge is a true plug and play device. Out-of-the-box, the system takes only a few minutes to set up. Software included and pre-installed in the package is the Cepton SDK, CeptonViewer and the Perception Server. The hardware features compact, lightweight design and has ports for 1Gb Ethernet, HDMI, USB 3.0 and USB 2.0 connections, and can function on IoT and Wi-Fi networks.

About Cepton Technologies, Inc.

Cepton Technologies, Inc. is a 3D sensing solutions provider shipping next-generation lidar-based products for the security, smart infrastructure, transport and retail markets. For more information, visit http://www.cepton.com/ .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye